key: cord-0908108-mhfncx8h authors: Sayad, Babak; Sobhani, Mahsa; Khodarahmi, Reza title: Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were we Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial? date: 2020-04-29 journal: Arch Med Res DOI: 10.1016/j.arcmed.2020.04.018 sha: 140e5da34e8cc4e2427d63e9d0d11f911505e5c2 doc_id: 908108 cord_uid: mhfncx8h COVID-19 is a devastating global pandemic around the world. While the majority of infected cases appear mild, in some cases individuals present respiratory complications with possible serious lung damage. There are no specific treatments for COVID-19 as yet, though a number are under evaluation, including experimental antivirals. Sofosbuvir, the clinically approved anti-hepatitis C virus (HCV) drug, is also capable of suppressing other families of positive-strand RNA viruses; Flaviviridae and Togaviridae. Coronaviruses are a family of positive-strand RNA viruses with conserved polymerase, so SARS-CoV-2 RdRp is very likely to be effectively inhibited by sofosbuvir. More importantly, sofosbuvir is safe and well tolerated at 400 mg daily in a 24 week therapeutic regimen. Sofosbuvir active metabolite, however, shows an extremely high intracellular stability So, it is hypothesized that SARS-CoV-2 infection could also be susceptible to sofosbuvir and we were convinced to design and run a clinical trial to evaluate the effect of sofosbuvir 400 mg (in combination with velpatasvir 100 mg, as add-on treatment, in addition to standard of care) on the COVID-19. However, we believe that this manuscript/correspondence should be made available to the international scientific community as soon as possible, with the help of this esteemed journal. More importantly, sofosbuvir is safe and well tolerated at 400 mg daily in a 24 week therapeutic regimen. Sofosbuvir active metabolite, however, shows an extremely high intracellular stability So, it is hypothesized that SARS-CoV-2 infection could also be susceptible to sofosbuvir and we were convinced to design and run a clinical trial to evaluate the effect of sofosbuvir 400 mg (in combination with velpatasvir 100 mg, as add-on treatment, in addition to standard of care) on the COVID-19. However, we believe that this manuscript/correspondence should be made available to the international scientific community as soon as possible, with the help of this esteemed journal. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its related disease, COVID-19 is terribly spreading to 206 countries, areas or territories. Till April 2 nd , 2020, the values of confirmed cases and total deaths were more than 896,000 and ~45,500 (https://www.who.int/emergencies/diseases/novel-coronavirus-2019). Human pathogenic coronaviruses (SARS-CoV and SARS-CoV-2) bind to their target cells through angiotensinconverting enzyme 2 (ACE2), which is expressed by epithelial cells of the lung, intestine, kidney, and blood vessels (1) (2) (3) . The ability of SARS-CoV2 to enter and infect the human nervous system, based on the strong expression of the ACE2 target throughout the brain (4), should be also considered. However, despite decades of extensive research, there are no specific/effective therapies approved by Ritonavir), and its actual role in the treatment of COVID-19 is still unclear, some preclinical data suggested potential benefit. However, more recent data has failed to confirm Kaletra efficacy for COVID-19 treatment (5) (https://www.elsevier.com/__data/assets/pdf_file/0007/988648/COVID-19-Drug-Therapy_Mar-2020.pdf). While the COVID-19 outbreak continues to spread around the world, the absence of a clinically proven antiviral therapy is a serious challenge for the treatment of severe COVID-19 cases (6). According to (7) and (8) Figure 1 ), Tenofovir alafenamide, Alovudine, and AZT were incorporated by RNA-dependent RNA polymerase (RdRp) enzymes of SARS-CoV as well as SARS-CoV-2, and permanently blocked further incorporation (further polymerase extension was terminated). They considered all these compounds as permanent/strong terminators for the SARS-CoV-2 RdRp (7, 8) . Due to widely availability of these FDA approved drugs (Sofosbuvir, Tenofovir and AZT), they expressed hope that the drugs would be more evaluated quickly in laboratory and clinical trials for COVID-19 treatment. But the above researchers (Chien M, et al.) could not offer one (or more) of them as the best RdRp inhibitor(s) to introduce to the scientific community. Sofosbuvir is a clinically approved drug with potent antiviral effects against hepatitis C virus (HCV) with diverse genotypes (11) . The acid dissociation constant (pKa) of sofosbuvir is around 9.3 and as the class 3 compound possess high-solubility and low-permeability (12) . The phosphorylation of sofosbuvir within the host cell (hepatocyte) converts it to the active from, nucleoside triphosphate, which terminates RNA replication in the nascent viral genome through the competition with the nucleotides of virus (11) . Sofosbuvir exhibits potent antiviral activities, >90%, even against liver cirrhosis, as well as prior null response to ribavirin and IFN (13) . Moreover, sofosbuvir is fast response and estimated that during the mean 0.8 and 2 d it exerts it 99 and 99.9 % potency (14) . Sofosbuvir offers high healing rate, low side effects, significant efficacy, short administration period good tolerability, and potent resistance defense (15) (e.g. FISSION (16) , POSITRON (17), FUSION (17) , PHOTON-1 (18) . It is reported that the patients receiving combination of sofosbuvir and ribavirin with or without interferon-α did not express primary sofosbuvir resistance mutation in NS5B, S282T (15, 19) . Moreover, sofosbuvir exerts pan-genotypic antiviral effects against HCV genotypes 1-6 (20). This antiviral drug does not interfere with major drug metabolizing enzymes, such as the cytochrome Arch Med Res E20_488 5 P450 system, therefore has low drug-drug interactions, including with antiretrovirals, opioid substitution therapy, and calcineurin inhibitors, which is beneficial for treatment of who have traditionally been difficult to treat. Sofosbuvir has rapid clinical development due to its high efficacy and safety profile (21) . Moreover, sofosbuvir can be prescribed in an oral single daily dose due to its promising pharmacokinetic profile. The bioavailability of sofosbuvir is high with maximum plasma concentrations (C max ) at ≈ 0.5-2 h in the oral administration (22) . It is interesting that Sofosbuvir, the clinically approved anti-hepatitis C virus (HCV) drug, has the ability to suppress different families of viruses. Different research groups have demonstrated that this safe drug inhibits the replication of flaviviruses (including ZIKV and DENV, and yellow fever virus (YFV) (23) (24) (25) (26) (27) (28) . Moreover, Ferreira AC, et al. (9) observed that, beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication. They found that sofosbuvir was three times more selective in inhibiting Chikungunya virus (CHIKV) production and also was 25% less cytotoxic, in human hepatoma cells, than ribavirin. CHIKV is a member of the Togaviridae family has a positive-sense single-stranded RNA genome and its RdRp enzyme (is coded by NsP4 gene), as with other RNA polymerases from positive-sense RNA viruses (29) , has well-conserved motifs. In this regard, since coronaviruses are a family of enveloped positive-strand RNA viruses with conserved polymerase, SARS-CoV-2 RdRp is very likely to be effectively inhibited by sofosbuvir. So, we hypothesized that SARS-CoV-2 infection could also be susceptible to this drug. Prior to the discovery of sofosbuvir, a variety of nucleoside analogs had been examined as antihepatitis C (HCV) treatments, but this exhibited relatively low potency. Owing to the substrate specificity of the kinases, the activation of nucleoside analogues often proceeds insufficiently. The design of sofosbuvir, avoids this slow step by building the first phosphate group into the structure of the drug during synthesis. Moreover, additional groups are attached to this phosphate (to temporarily Arch Med Res E20_488 6 mask the negative charges of the phosphate group, thereby) facilitating entry of the pro-drug into the infected cell (30) . Although hepatic cells have the most effective system for removing sofosbuvir phosphate protection, functional assays have revealed that other cells, relevant to SARS-CoV-2 infection, also activate sofosbuvir (9,31). One of principle cell types productively infected by CHIKV are epithelial cells and variety of nonhuman and human epithelial cell lines (32) . As mentioned above, sofosbuvir is (metabolized to the active drug and) capable of efficient controlling of this type of virus inside the epithelial cells. Furthermore, sofosbuvir appears to be highly active against ZIKV in human neuroepithelial stem cells (24, 26) suppression, in different infected cell lines, could be explained by differences in intracellular processing of the pro-drug, leading to different concentration of the active triphosphate metabolite (33) . The extent of drug uptake and cytosolic levels of metabolizing enzymes (such as NDK), involved in the metabolic activation of sofosbuvir in the infected cells, are two main determinants. Other important enzyme is carboxylesterase 1 (CES1) which is needed for activation of sofosbuvir. The hepatic cells strongly express CES1 and lower levels of the enzyme expression, however, is documented in the lung cells (35, 36) . Though, sofosbuvir, developed for treatment of a hepatotropic virus, is designed to facilitate the intracellular penetration in liver tissue, the above statements can, in part, explain the successful uptake and intracellular activation of sofosbuvir in alveolar epithelial cells, as a viral reservoir. We may also assume that cellular uptake of the pro-drug (sofosbuvir) as well as intracellular concentrations of biologically active triphosphate metabolites within lung epithelial cells are low, though local lung inflammation may enhance endothelial permeability and then improve epithelial uptake of the drug in the disease state. Which feature of sofosbuvir may give hope? That may be intracellular stability of the triphosphate metabolite. The surprising differences in stability of nucleoside analogue triphosphates of nucleotide analogues have been reported. It has been shown that the triphosphate of the Sofosbuvir showed an extremely high intracellular stability (~35 h), which was also made responsible for the significant and persistent anti-HCV effect of active drug to inhibit NS5B-polymerase (37) . Babusis D, et al. also confirmed this observation and evaluated In vitro metabolism of sofosbuvir and ribavirin in primary human hepatocytes (38) . They showed that activation was efficient for two investigated drugs, but the triphosphate metabolite of sofosbuvir Overall, although sofosbuvir is not currently listed as potential option of COVID-19 drug therapy, till now (https://www.elsevier.com/__data/assets/pdf_file/0007/988648/COVID-19-Drug-Therapy_Mar-2020.pdf), the evidence on the advantageous action of this drug on viral RdRp in vitro, stability of triphosphate drug metabolite and "the least interaction with standard of care" constituted the rationale to perform a trial on patients with SARS-CoV-2 infection. Moreover, sofosbuvir is safe and well tolerated at 400 mg daily in a 24 week therapeutic regimen (9), clinically relevant drug-drug interactions are rare and its important drug interaction is with amiodarone, which causes bradycardia (Sovaldi [Sofosbuvir]: Prescribing information. Foster City, CA: Gilead Sciences; 2013). Sofosbuvir presents an unusually clean safety profile for a nucleotide therapeutic. The safety profile of sofosbuvir, either in combination with Peg-IFN and RBV or in combination with ribavirin alone in all-oral regimen, was excellent, even in cirrhotic patients. Also, In vitro, sofosbuvir exhibits no cytotoxicity, mitochondrial toxicity, or bone marrow toxicity when dosed at multiples above the effective dose (40, 41) . So, we were convinced to design and run a clinical trial to evaluate the effect of sofosbuvir 400 mg (in combination with velpatasvir 100 mg, as add-on treatment, in addition to standard of care) on the COVID-19. The written research proposal was submitted to the University research council/Ethics Committee, then the approved proposal registered in the Iranian Registry of Clinical trials (code: https://www.irct.ir/trial/46790). The clinical trial is currently in process. In agreement with (9), we advocate generic sofosbuvir beyond treatment of HCV-infected patients. As it represents a safe and Arch Med Res E20_488 9 effective antiviral option, compared to similar anti-viral agents, we encourage clinical investigators to consider these dual-component HCV drugs, (velpatasvir/sofosbuvir), as re-purposed treatment against SARS-CoV-2 infection. However, we believe that this manuscript/correspondence should be made available to the international community as soon as possible, with the help of this esteemed journal. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection Does COVID19 infect the brain? If so, smokers might be at a higher risk A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Practical Strategies Against the Novel Coronavirus and COVID-19-the Imminent Global Threat Nucleotide Analogues as Inhibitors of SARS-CoV-2 Nucleotide Analogues as Inhibitors of SARS-CoV Polymerase Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938 No Resistance Detected in four Phase 3 Clinical Studies in HCV Genotype 1-6 of Sofosbuvir+ Ribavirin with or without Peginterferon: 1843 Sofosbuvir for previously untreated chronic hepatitis C infection Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1) Comprehensive Resistance Testing in Patients Who Relapsed after Treatment with Sofosbuvir (GS-7977)-Containing Regimens in Phase 2 Studies: 753 In Vitro Pan-genotypic and Combination Activity of Sofosbuvir (GS-7977) in Stable Replicon Cell Lines: 1875 New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C Pharmacokinetic, pharmacodynamic, and druginteraction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir Sofosbuvir protects Zika virus-infected mice from mortality, preventing short-and long-term sequelae The FDA-approved drug sofosbuvir inhibits Zika virus infection The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication Zika virus disrupts phospho-TBK1 localization and mitosis in human neuroepithelial stem cells and radial glia Evaluation of Sofosbuvir (β-D-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine) as an inhibitor of Dengue virus replication Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977 Nucleoside diphosphate kinase A as a controller of AMPkinase in airway epithelia The cell biology of C hikungunya virus infection Cell-line dependent antiviral activity of sofosbuvir against Zika virus The NDPK/NME superfamily: state of the art The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue Nature and role of xenobiotic metabolizing esterases in rat liver, lung, skin and blood Nucleoside diphosphate and triphosphate prodrugs-An unsolvable task? Sofosbuvir and ribavirin liver pharmacokinetics in patients infected with hepatitis C virus Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates PSI-7851, a pronucleotide of β-D-2′-deoxy-2′-fluoro-2′ is a potent and pan-genotype inhibitor of hepatitis C virus replication Overall efficacy and safety results of sofosbuvir-based therapies in phase Arch Med Res E20_488 15 II and III studies